Axogen, Inc. shares are experiencing a notable uptick following a positive forecast issued by Leerink Partners. On November 25, 2024, the investment analysts at Leerink Partners raised their earnings per share (EPS) estimates for Axogen's fiscal year 2024. The revised forecast now anticipates an EPS of ($0.31), slightly improved from the previous estimate of ($0.32). This adjustment reflects a more optimistic outlook for the company's financial performance, which has likely contributed to the increased investor interest.
Additionally, Axogen has been receiving favorable attention from other analysts, with StockNews.com recently upgrading the stock from a "hold" to a "buy" rating. The company currently holds a consensus "buy" rating from five analysts, with an average price target of $15.00, according to MarketBeat. This positive sentiment from the analyst community may be bolstering investor confidence in the stock.
Axogen's stock is up 10.21% pre market, reaching $15.00 as of 8:32 am on November 27, 2024, compared to the previous close of $13.61.